Type/Product Area

Terms/Details (Date)

Acambis plc (UK;


Cambridge Biostability
licensed rights to Acambis' enterotoxigenic E. coli vaccine against travelers' diarrhea

Acambis retained an option for an exclusive license to market the vaccine, HolaVax-ETEC, in North America; terms of the deal were not disclosed (5/10)

Access Pharmaceuticals Inc. (AMEX:AKC)


Collaboration for the oral
delivery of a drug candidate
for Alzheimer's disease

They will combine Access's vitamin B-12 oral delivery technology with Hunter-Fleming's Oligotropin (HF0420); terms of the deal were not disclosed (5/12)


Lexicon Pharmaceuticals

ActiveSight will perform crystallography services
for Lexicon

The deal extends the co-crystallography of Lexicon's small-molecule compounds to a second drug-target protein validated by Lexicon and expressed by ActiveSight; terms were not disclosed (4/27)

Affitech A/S*

UK-based company

The unnamed company gets rights to use the Protein L gene as well as vectors and know-how of Protein L production

The nonexclusive license covers use with (Norway) research and preclinical development; terms of the deal were not disclosed (5/31)


Genmab A/S

Genmab got rights to access AlgoNomics' Epibase platform for T-cell epitope identification

Genmab will use the technology in validation of antibody leads; terms of the three- year deal were not disclosed (5/12)

Alnylam Pharmaceuticals Inc. (ALNY)

Ambion Inc.*

Ambion got rights to provide research products and services under Alnylam's Kreutzer- Limmer patent family

The patents cover short interfering RNAs and their use to mediate RNAi in mammalian cells; terms of the nonexclusive license were not disclosed (6/8)

Angiotech Pharmaceuticals Inc. (Canada; ANPI)


Histogenics got rights to use
the biomaterial ChondroGEL
in cartilage, ligament, meniscus and/or tendon repair

Angiotech gets warrants to purchase Histogenics shares, and would share any resulting revenue; it also retains all drug-loaded rights to ChondroGEL (6/2)

Angiotech Pharmaceuticals Inc. (Canada;

Broncus Technologies

Broncus got rights to use Angiotech's Paclitaxel technology with its Exhale system for treating

Angiotech gets warrants to purchase Broncus preferred stock, and would get royalties on sales of resulting products (6/2)

Asinex Ltd.*

(Belgium; Euronext:GLPG)

Collaboration to optimize leads for Galapagos' validated bone and joint disease drug targets

Asinex will use its computational chemistry and compound libraries to generate new leads; then they will design and optimize the lead structures; terms were not disclosed (5/12)

Atugen AG*



Atugen will use its siRNA technology to validate a Xantos angiogenic compound in animal studies

Terms of the deal were not disclosed (4/15)#

BioMarin Pharmaceutical

Serono SA
(Switzerland; NYSE:SRA)

Collaboration to further develop and commercialize two BioMarin products, Phenoptin and Phenylase, for treating phenylketonuria and possibly other diseases

BioMarin gets $25M up front and up to $232M in milestone payments based on the registration of both products in multiple indications, as well as royalties on sales; Serono gets exclusive rights outside the U.S. and Japan (5/16)

BioWa Inc.*

Medarex Inc.

Medarex got a second license to BioWa's Potelligent technology for enhancing antibody- dependent cellular cytotoxicity

BioWa gets license fees, and could receive milestone payments and product royalties; Medarex has nonexclusive rights to develop antibodies for an undisclosed number of targets (5/24)

Caliper Life
Sciences Inc.

Affymetrix Inc.

Affymetrix got nonexclusive rights to use Caliper's microfluidics technology with Gene-Chip microarray technologies

The deal covers all GeneChip applications; Caliper gets an up-front license fee and (CALP) royalties on future sales covered under the deal (4/25)


Group plc

BioInvent International

BioInvent got rights to use CAT's antibody phage-display technology to develop products from its n-CoDeR antibody libraries

CAT gets an initial license fee and future payments that depend on how many anti- bodies BioInvent and its partners develop using the technology; CAT also is entitled to milestone and royalty payments; as part of the deal BioInvent withdrew its opposition to CAT patents filed in Europe (6/3)

Cellectis SA*

Celliance (unit of
Serologicals Corp.; SERO)

Celliance will evaluate
Cellectis' Meganuclease Recombination System

The goal is to develop a new generation of cell lines; terms of the deal were not disclosed (5/31)

Cell Signaling Technology

Chiron Corp.

CST will perform a pilot project for Chiron using its PhosphoScan technology

The goal is to identify phosphorylation sites and prospective biomarkers of protein tyrosine kinase targets; terms of the deal were not disclosed (6/1)

Cell Therapeutics

Cephalon Inc.

Cephalon acquired Trisenox (arsenic trioxide), a product approved for treating acute promyelocytic leukemia

CTI gets $70M in cash and up to $100M more if certain sales and regulatory milestones are achieved; Cephalon also got rights to a joint proteasome inhibitor research program, and would pay royalties on any resulting sales from that program; Cephalon will offer jobs to CTI commercial employees (6/13)

ChemBridge Research Laboratories Inc.*

Trimeris Inc.

Collaboration to discover and develop small-molecule HIV entry inhibitors, targeting gp41 and gp120

CRL gets funding to support medicinal chemistry efforts, and is eligible to receive milestone payments and sales royalties; Trimeris assumes development and commercial responsibilities (6/13)

Chiron Corp.

Enanta Pharmaceuticals

Exclusive deal to develop and commercialize Chiron's portfolio of hepatitis C virus protease inhibitors

Chiron is entitled to milestone and royalty payments, and retains certain co-development and commercialization opt-in rights, excluding Asia; Enanta also got nonexclusive rights to certain HCV technology (5/19)

Crucell NV
(the Netherlands;

Medarex Inc.

Program to optimize the application of Crucell's STAR technology in bioreactor

The program will be performed with a fully human antibody developed using Medarex's UltiMAb technology; terms were not disclosed (6/1)

Holdings plc*


Biomoda Inc.*

Cytomyx will provide human clinical samples for Biomoda's program to develop diagnostics

The samples will support validation work on Biomoda's products for detection and targeted treatment of certain cancers; terms of the deal were not disclosed (5/3)

Definiens AG*

Cenex BioScience

They formalized an ongoing relationship through the signing of a licensing and co-marketing agreement

They will work together in the area of high-content screening on a worldwide, non-exclusive basis; terms of the deal were not disclosed (5/9)

Depomed Inc.

New River

Deal to use Depomed's oral Gastric Retention delivery technology with New River drug compounds

New River may acquire rights to use the technology in up to three compounds; Depomed would get an initial payment and potential milestone and royalty payments for each compound advanced (6/6)

Dharmacon Inc.
(unit of Fisher Biosciences)

Millennium Pharmaceuticals

Dharmacon will deliver a genome-wide siRNA library covering about 22,000 human genes to Millennium

The library will enable high-throughput functional genomic studies for target identification and validation; terms of the deal were not disclosed (5/5)


Starpharma Holdings Ltd.

They entered a joint venture focused on dendrimer-based GPCR drug discovery and development

The venture will use Dimerix's Collision technology in the effort; Starpharma formed Dimerix and holds a 30% stake in the start-up company (5/11)

Encysive Pharmaceuticals

Revotar Bio- pharmaceuticals
(Germany; majority owned by Encysive)

Deal under which Revotar would license bimosiamose and certain follow-on compounds

The deal is contingent on Revotar's other stockholders investing additional capital in Revotar, which would reduce Encysive's ownership to about 14%; Encysive would get royalties on sales (4/26)

EndoBiologics International Corp.*

VaxGen Inc.

Collaboration for research of a vaccine against meningitis serogroup B, using technology developed by EndoBiologics

VaxGen will fund proof-of-concept studies for a year; if it then exercises its option, VaxGen would provide additional research funding, while EndoBiologics would be entitled to milestone and royalty payments (5/4)

(Germany; FSE:ECX)

Qiagen NV
(the Netherlands;

Deal to develop a preanalytical solution portfolio for DNA methylation analysis

The goal of the collaboration is to develop diagnostic kit components; Epigenomics gets up-front technology access and license fees, as well as royalties on all research product sales (5/2)


Genmab A/S

Genmab acquired all rights to 16 potential targets to treat non-steroid-dependent cancers of epithelial cell origin

There are no milestone or royalty obligations in the deal; Europroteome is in insolvency proceedings (5/18)

Exelixis Inc.

Genentech Inc. (NYSE:DNA)

Collaboration to discover and develop therapeutics targeting cancer, inflammatory diseases and tissue growth and repair; the work focuses on the Notch pathway

Exelixis gets up-front and three years of R&D funding totaling $16M; it also is entitled to milestone and royalty payments; Exelixis also has an option to share part of the costs and profits for certain products (6/3)

GeneGo Inc.*

Exelixis Inc.

Exelixis licensed GeneGo's MetaCore technology

The platform is used in drug discovery; terms of the deal were not disclosed (5/13)

Genmab A/S (Denmark; CSE:

Serono SA
(Switzerland; NYSE:SRA)

Serono got worldwide rights to Genmab's HuMax-TAC, a fully human monoclonal antibody being developed for T-cell-mediated diseases

Genmab gets an up-front payment of $2M and is entitled to milestone payments of up to $38M, as well as royalties on sales from any resulting products; the product is in the preclinical stage (5/2)

Icoria Inc.



Deal under which Icoria will profile Vesta's adult human liver-derived stem/progenitor cells

In return, Icoria will gain access to clinical liver samples for use in validating biomarkers and drug targets (4/27)


Genentech Inc.

They renewed May 2000 agreement giving Genentech certain rights to use ImmunoGen's Tumor- Activated Prodrug technology

Genentech paid $2M to renew the deal for three years; the original deal was for five years (5/2)


Genentech Inc.

Genentech licensed rights
to use Tumor-Activated Prodrug technology with therapeutic antibodies for an undisclosed target

ImmunoGen gets a $1M license payment and is entitled to milestone and royalty payments; the exclusive deal stems from a pact in 2000 giving Genentech rights to test the technology against certain targets (4/28)

Systems Inc.*

Serono Genetics Institute (France; unit of Serono SA; NYSE:SRA)

Serono licensed the Pathways Knowledge Base for use in developing drug discovery and development tools

Serono also licensed the Pathways Analysis application; terms of the deal were not disclosed (6/14)


Three Rivers Pharmaceuticals

Three Rivers acquired worldwide ownership of Amphotec/Amphocil (lipid-based amphotericin B)

The product is indicated for treating invasive aspergillosis; terms of the deal were not disclosed (5/24)


Acuity Pharmaceuticals

Acuity got exclusive rights to Intradigm's technology for topical and systemic drug delivery for ophthalmic uses

They also will collaborate to develop topical formulations of Acuity's Cand5 com- pound; Acuity exclusively licensed rights to Intradigm's siRNA ophthalmic discovery technologies; the deal includes up-front payments and potential milestones and royalties to Intradigm (6/9)

Kalypsys Inc.*

NovImmune SA* (Switzerland)

Collaboration to discover
and develop small-molecule modulators of the major histocompatibility complex II for treating autoimmune and inflammatory diseases

They will pair Kalypsys' screening technology, chemical library and small-molecule capabilities with NovImmune's expertise in immunoregulation and MHC Class II-associated biology; terms were not disclosed (6/16)

Luminex Corp.

Digene Corp.

Digene gained access to Luminex's xMAP bead-based multiplexing technology for use in women's health diagnostics

Digene intends to commercialize in vitro clinical diagnostic tests under the non-exclusive license; terms of the deal were not disclosed (5/5)


InterveXion Therapeutics

Deal to use Medicago's
Proficia Protein Technology to produce monoclonal antibodies designed to treat drug abuse

Medicago would get milestone payments to produce the phencyclidine (PCP) antibody; an expanded deal to include another antibody is expected (6/6)

Mera Pharmaceuticals Inc. (OTC

Rincon Pharmaceuticals

Collaboration to demonstrate the scalability and economics of using microalgae as a protein expression system

Mera will use its technology to perform pilot studies on up to six antibodies; Rincon has an option to use the technology to develop its own production capability; terms were not disclosed (5/12)

Myriad Genetics

Salmedix Inc.*

Salmedix got exclusive rights to use the single R-enantiomer of etodolac

The license provides additional protection to Salmedix for its cancer candidate SDX-101; Myriad gets $2.5M up front and is entitled to milestone and royalty payments (5/24)

Co. Ltd.*

Debiopharm SA* (Switzerland)

Debiopharm got an option to license a DACH Platin Medicelle platinum-based compound for oncology applications

Debiopharm will fund product development; NanoCarrier is entitled to receive milestone payments and royalties on any sales (4/21)

NovImmune SA* (Switzerland)

Serono SA (Switzerland; NYSE:SRA)

Serono got worldwide rights to two fully human monoclonal antibodies, NI-0401 and NI-0501, which may have potential in autoimmune diseases

NovImmune gets a $5M license fee, a $6M equity investment, and a convertible loan of up to $6M; it also could get up to $105M in milestone payments, as well as royalties on sales (5/17)



Nuevolution will use its Chemetics technology to discover new drug leads against a Biovitrum target

Nuevolution is entitled to certain milestone payments and a share of any future product sales (6/13)

OncoMethylome Sciences SA* (Belgium)

Exact Sciences

Deal to evaluate certain gene methylation markers for use with Exact's colon cancer screening technology

The markers were identified at Johns Hopkins University and are exclusively licensed to OncoMethylome; terms of the deal were not disclosed (6/7)

OriGene Technologies

Regeneron Pharmaceuticals

Regeneron got a license to OriGene's TrueClone collection of full-length human cDNAs

Regeneron will use the technology in its protein expression and target validation platforms; terms were not disclosed (4/27)

Penwest Pharmaceuticals

Prism Pharmaceuticals

Prism got exclusive rights to market Penwest's beta-blocker PW2101 in the U.S. and Canada

The product is under review by the FDA for treating hypertension and angina; Penwest got $4M up front and could get $9.5M in milestones if the product is approved by Dec. 31, 2005; Penwest would get royalties of 15% to 18% (4/27)

Seattle Genetics


MedImmune got rights to use antibody-drug conjugate technology with antibodies against a single tumor target

Seattle Genetics gets $2M up front and annual maintenance fees, and is entitled to milestone and royalty payments; Med- Immune also has an option to access the technology for a second antibody program for an additional fee (4/28)

(the Netherlands)

Genmab A/S

Genmab will evaluate To-BBB's technology for delivering antibodies across the blood-brain barrier

Genmab has an option to license the technology for use with two antibodies; To-BBB is eligible to receive milestone and royalty payments (5/24)


A.C.T. Holdings

A.C.T. and subsidiary Advanced Cell Technology Inc. got an option for exclusive rights to cloning patents

Separately, A.C.T. acquired rights to a cloning technology known as "cell fusion" and patents related to gene trap technology; terms of the deal were not disclosed (5/19)

Vical Inc.

AnGes MG

AnGes gained exclusive rights to use Vical's nonviral gene delivery technology for cardiovascular applications

The license covers DNA-based products encoding hepatocyte growth factor; Vical gets $1M up front, and is eligible for milestone and royalty payments (5/24)


* Private companies are indicated with an asterisk.

# Item occurred before the time frame of this chart but was not included in the previous chart.

Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; SSE = Stockholm Stock Exchange.